(Q46648243)

English

188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study

scientific article published in August 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

Andreas K. Buck

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

Stephanie von Harsdorf

5

object named as

Stephanie von Harsdorf

0 references

Stephan Stilgenbauer

12

object named as

Stephan Stilgenbauer

0 references

Hartmut Döhner

13

object named as

Hartmut Döhner

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

9

object named as

Thorsten Zenz

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

author name string

Mark Ringhoffer

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

Norbert Blumstein

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

Gerhard Glatting

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

Stephanie von Harsdorf

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

Inga Buchmann

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

Markus Wiesneth

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

Jörg Kotzerke

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

Peter Schauwecker

11

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

Sven N Reske

14

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

Donald Bunjes

15

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

language of work or name

0 references

publication date

1 August 2005

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

130

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

604-613

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05663.X

21 January 2018

Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05663.X

21 January 2018

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05663.X

21 January 2018

Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05663.X

21 January 2018

Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05663.X

21 January 2018

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05663.X

21 January 2018

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05663.X

21 January 2018

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05663.X

21 January 2018

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05663.X

21 January 2018

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05663.X

21 January 2018

The use of radioimmunoconjugates in stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05663.X

21 January 2018

CD34 cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05663.X

21 January 2018

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05663.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2005.05663.X

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098076

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46648243&oldid=2124258239"